Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy | MicrobiomeTrials← Back to trialsNCT07493395
Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-08-01Est. Completion: 2026-08-01
Enrollment target: 6 participants Locations- CHRU Lille, Lille, France
- Montpellier University Hospital, Montpellier, France
- APHP Necker, Paris, France
- Chu Rouen, Rouen, France
Other microbiome trials you might be interested in
Refractory/Relapsed Systemic Lupus ErythematosusRefractory / Relapsed / Progressive Systemic SclerosisRefractory / Relapsing / Progressive Inflammatory MyopathyRefractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated VasculitisRefractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-…
Multiple LocationsEst. completion Dec 31, 2028
Autoimmune Diseases
Background:
Autoimmune diseases can be caused by genes people inherit from their parents. The gene changes that cause t…
Bethesda, United StatesEst. completion Apr 22, 2030